Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

partially engineered T-regulatory cell donor graft TRGFT-201

A T-regulatory (Treg) cell donor graft that has been partially engineered by depleting all the T cells and then enriching the graft with infusions of conventional T-cells, Tregs and CD34+ stem cells derived from peripheral blood from either related or unrelated matched donors, with potential immunomodulating activity. Upon administration of the partially engineered T-regulatory cell donor graft TRGFT-201 following myeloablation, the allograft may induce tolerance in patients undergoing allogeneic hematopoietic stem cell transplantation (AHSCT) as treatment for hematologic malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:partially engineered and enriched Treg donor graft TRGFT-201
T-cell-depleted graft with additional infusion of conventional T cells and regulatory T cells
US brand name:Orca-T
Code name:TregGraft
TRGFT 201
TRGFT-201
TRGFT201
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search